Continuous downstream processing
Alois Jungbauer (BOKU-University of Natural Resources and Life Sciences, Austrian Centre of Industrial Biotechnology (ACIB GmbH))
Peter Satzer (Austrian Centre of Industrial Biotechnology GmbH, BOKU-University of Natural Resources and Life Sciences)
Astrid Duerauer (Austrian Centre of Industrial Biotechnology GmbH, BOKU-University of Natural Resources and Life Sciences)
Ana Azevedo (Universidade Técnica de Lisboa)
Raquel Aires-Barros (Universidade Técnica de Lisboa)
Bernt Nilsson (Lund University)
Suzy Farid (University College London)
Stephen Goldrick (University College London)
Marcel Ottens (TU Delft - BT/Design and Engineering Education)
undefined More Authors (External organisation)
More Info
expand_more
Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.
Abstract
The main objectives of bioprocesses are to reliably deliver drugs in a relatively short time frame with high quality within a tight regulatory framework. Bioprocesses are highly complex, the level of automation is moderate, and there is constant pressure to improve efficiency and costs. In addition, climate change and resource scarcity mandate a reduction in the environmental footprint of bioprocesses and production facilities. In the biopharmaceutical industry, two extreme production scenarios are applied: a fully disposable factory with the characteristics of full flexibility and speed, or a fixed large-scale plant with high capacity. Forward-looking solutions and ideas will be discussed how to combine new processes and environmental friendliness for the benefit of the patient, security of supply and profitability. The concept will be extended to large scale production of proteins for food and non-pharma applications, e.g., in material science and a roadmap towards a future plant will be laid out.
help_outline